Phase II multicenter sequential study of docetaxel (T) and epirubicin (E) followed by docetaxel (T) and capecitabine (X) as first-line treatment of advanced or metastatic breast cancer (MBC).

被引：0
作者：
Ramos, M
Casal, J
Galán, A
Almanza, C
León, L
Amenedo, M
Gonzalez, A
Huidobro, G
Giner, V
机构：
[1] Ctr Oncol Galicia, La Coruna, Spain
[2] Hosp Meixoeiro, Vigo, Spain
[3] Hosp Sagunto, Valencia, Spain
[4] Clin Povisa, Vigo, Spain
[5] Hosp Clin Santiago, Santiago De Compostela, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：54S / 54S
页数：1
相关论文
共 50 条
[31]   WEEKLY EPIRUBICIN AND DOCETAXEL AS FIRST-LINE CHEMOTHERAPY IN METASTATIC BREAST CANCER [J].
D'Ottavio, A. ;
Vaccaro, A. ;
Belli, F. ;
Nunziata, C. ;
Meliffi, L. ;
Moscetti, L. ;
Barduagni, M. ;
Sperduti, I. ;
Gamucci, T. .
ANNALS OF ONCOLOGY, 2004, 15 :19-19
[32]   Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer:: a GEICAM-9801 phase II study [J].
Alba, E ;
Ribelles, N ;
Antón, A ;
Pérez-Carrión, R ;
López-Vega, JM ;
Llanos, M ;
Pelegri, A ;
Florián, J ;
Menéndez, M ;
Godes, MJ .
BREAST CANCER RESEARCH AND TREATMENT, 2003, 77 (01) :1-8
[33]   Phase II Multicenter Study of Docetaxel and Bevacizumab With or Without Trastuzumab as First-Line Treatment for Patients With Metastatic Breast Cancer [J].
Schwartzberg, Lee S. ;
Badarinath, Suprith ;
Keaton, Mark R. ;
Childs, Barrett H. .
CLINICAL BREAST CANCER, 2014, 14 (03) :161-168
[34]   Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer [J].
Musolino, A. ;
Bisagni, G. ;
De Matteis, A. ;
Nuzzo, F. ;
Ardizzoni, A. ;
Crino, L. ;
Gamucci, T. ;
Passalacqua, R. ;
Gnoni, R. ;
Boni, C. .
CANCER RESEARCH, 2010, 70
[35]   Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer [J].
Venturini, M ;
Del Mastro, L ;
Garrone, O ;
Angiolini, C ;
Merlano, M ;
Bergaglio, M ;
Tolino, G ;
Lambiase, A ;
Baldini, A ;
Canavese, G ;
Rosso, R .
ANNALS OF ONCOLOGY, 2002, 13 (04) :546-552
[36]   Trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: Phase II results [J].
Gennatas, C. G. ;
Michalaki, V. ;
Gennatas, S. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[37]   Docetaxel versus epirubicin/cyclophosphamide(EC) as first-line therapy in metastatic breast cancer (MBC): results from the randomized phase II TIPP study [J].
不详 .
BREAST, 2005, 14 :S41-S41
[38]   A phase I/II study of docetaxel/epirubicin/bevacizumab (DEB) as first-line therapy for metastatic, HER2-negative breast cancer (MBC). [J].
Mavroudis, D. ;
Boukovinas, I. ;
Christophyllakis, C. ;
Xenidis, N. ;
Papakotoulas, P. ;
Malamos, N. A. ;
Kakolyris, S. ;
Polyzos, A. ;
Georgoulias, V. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[39]   First-line chemotherapy of advanced or metastatic breast cancer (MBC) with docetaxel and doxorubicin in Indonesia: results from A phase II trial [J].
Abdulmuthalib ;
Darwis, Idral ;
Prayogo, Nugroho ;
Sutjipto .
MEDICAL JOURNAL OF INDONESIA, 2005, 14 (01) :20-25
[40]   First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients [J].
Liang, Xu ;
Yan, Ying ;
Wang, Lina ;
Song, Guohong ;
Di, Lijun ;
Jiang, Hanfang ;
Wang, Chaoying ;
Li, Huiping .
ONCOLOGY LETTERS, 2015, 9 (02) :987-993
12345